Study #2016-0785
A Phase II Study of Venetoclax (ABT-199) added to Ibrutinib in Patients with High-Risk CLL
Study Status
Open
Treatment Agent
Ibrutinib, Venetoclax
Principal Investigator
Philip A. Thompson
Description
The goal of this clinical research study is to learn if giving the drug venetoclax with ibrutinib can help to control the disease in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The safety of this combination treatment will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Ibrutinib, Venetoclax
Treatment Location: Only at MD Anderson
Sponsor: AbbVie
Study Status
IRB Review and Approval Date: 06/16/2017
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Philip A. Thompson
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789